Investigation Overview
A comprehensive investigation by Nikkei has unveiled alarming connections between a Chinese operation suspected of exporting precursor chemicals for fentanyl and a substantial crypto fraud scheme orchestrated through Japan. This network allegedly exploited Japanese internet domains and launched a counterfeit token named “Zksync.jp,” leading to significant financial losses for crypto investors, totaling over 100 million yen (exceeding $1 million). The counterfeit token closely mimicked ZKsync, an authentic Ethereum Layer 2 scaling solution developed by Matter Labs, though no links to the legitimate entity have been established.
Key Players in the Operation
At the heart of this operation is Hubei Amarvel Biotech, a company based in Wuhan, previously entangled in legal troubles pertaining to fentanyl charges. Two executives from Amarvel were acquitted of major fentanyl-related allegations in 2025 but were found guilty of conspiring to import chemical precursors linked to fentanyl as well as of money laundering activities.
According to the Nikkei report, a Nagoya-based firm named Firsky acted as a Japanese front for the Chinese network. Xia Fengzhi, a Chinese national, has been noted for his role in handling logistics and finances linked to Japan. Firsky was dissolved in July 2024, while the current whereabouts of Xia remain unknown.
Financial Connections and Investigative Findings
Using wallet addresses revealed during U.S. court proceedings, Nikkei traced financial movements connecting Amarvel’s operations with Japan. The investigation identified over 120 cryptocurrency transactions that linked the network to entities facing U.S. sanctions, pointing to potential money laundering activities. Many of these transactions were associated with the Wuhan Yuancheng Group, connected to Chuen Fat Yip, a Chinese individual implicated in a transnational drug trafficking scheme. The U.S. State Department has offered a reward of up to $5 million for information leading to Yip’s capture.
Fraudulent Token and Domain Registration
The fraudulent token utilized a Japanese domain extension, which generally requires registrants to have a Japanese address. The registration information suggests the domain owner is a Chinese individual based in Hong Kong, allegedly with financial ties to Amarvel. Chainalysis, a blockchain analysis firm, explained to Nikkei that using Japanese domains can enhance the perceived legitimacy of fraudulent sites to international users, a tactic often employed by criminal groups to exploit jurisdictions with good reputations.
Regulatory Context and Implications
This investigation emerges at a critical time when the Japanese government is striving to expand its regulated cryptocurrency market. Recently, Japan’s lower legislative chamber approved a bill that redefines the classification of crypto assets under the Financial Instruments and Exchange Act, alongside a tax proposal that aims for a 20% tax rate by 2028. This evolving regulatory landscape poses challenges as authorities attempt to deter exploitative activities while promoting legitimate crypto endeavors. In a related effort, the Drug Enforcement Administration (DEA) established a cooperation agreement with the Japan Coast Guard in May to bolster their fight against fentanyl trafficking.
Broader Implications for Cryptocurrency and Drug Trade
Further underscoring the intertwining of cryptocurrency with the synthetic drug trade, a report from TRM Labs indicated that 97% of 120 Chinese precursor chemical manufacturers they examined were accepting cryptocurrency, with these wallets accumulating upwards of $26 million in 2023. The Nikkei findings add a significant layer of complexity to the understanding of how digital currencies are being leveraged within the realm of illegal drug supply networks, particularly emphasizing the role of Japan as a potential base for such fraudulent activities.
